WASHINGTON — The U.S. Department of Veterans Affairs is launching a new clinical trial to explore whether a medication commonly used to treat diabetes and aid weight loss could also help treat alcohol use disorder.
The study will focus on semaglutide, a GLP-1 receptor agonist, to determine whether it can reduce alcohol consumption among veterans diagnosed with the disease. Researchers say the drug has drawn growing interest for its potential impact on brain pathways tied to reward and addiction.
The VA says more than 400,000 veterans nationwide have been diagnosed with alcohol use disorder, and the disease is estimated to affect nearly 11% of U.S. adults.
“This clinical trial reflects medical research that VA is uniquely situated to launch, and is aimed directly at benefitting veterans,” VA Secretary Doug Collins said in a press release. “By exploring emerging treatment options like the use of a GLP-1 for alcohol use disorder, we aim to expand the tools available to help veterans take control of their health and recovery.”
The study, known as the Cessation or Reduction of Alcohol Consumption in Veterans trial, will enroll more than 600 participants at 18 VA medical centers across the country. Veterans ages 18 to 80 with moderate to severe alcohol use disorder will receive weekly injections of either semaglutide or a placebo over a 24-week period, followed by a safety follow-up.
Researchers will track changes in alcohol use, overall health, and quality of life to evaluate whether the medication offers a meaningful new treatment option.
Interest in GLP-1 medications has grown in recent years beyond their primary uses. Emily’s Hope has previously reported on research suggesting that people prescribed GLP-1 or GIP medications, including Ozempic and Mounjaro, may have a significantly lower risk of opioid overdose, are less likely to develop new addictions, and show reduced rates of alcohol use disorder and other substance use disorders.
Recruitment for the trial began July 28. Veterans interested in participating can contact their local VA medical center or visit ClinicalTrials.gov for more information.
VA officials emphasize that patients should not attempt to self-medicate or replace established treatments with GLP-1 medications. Proven, evidence-based treatments for alcohol use disorder remain available through VA facilities, and patients are encouraged to consult a healthcare provider before making any changes to their care.
